Taxanes in the elderly: Can we gain as much and be less toxic?

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 3, 2009, Pages 262-271

  Biganzoli, Laura ^a   Licitra, Sara ^a   Moretti, Erica ^a   Pestrin, Marta ^a   Zafarana, Elena ^a   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

Elderly; Pharmacokinetics; Schedule; Taxanes

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; MITOXANTRONE; NANOPARTICLE; PACLITAXEL;

ADJUVANT THERAPY; ADVANCED CANCER; AGING; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PROSTATE CANCER; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 67349280245     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.017     Document Type: Review

References (36)

1. Aapro M.S. Progress in the treatment of breast cancer in the elderly. Ann Oncol 13 Suppl. 4 (2002) 207-210
2. Vestal R.E. Aging and pharmacology. Cancer 80 7 (1997) 1302-1310
3. Sotaniemi E.A., Arranto A.J., Pelkonen O., and Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61 3 (1997) 331-339
4. http://www.cancercare.on.ca/index_drugFormularymonographs.htm
5. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15 9 (2004) 1358-1365
6. Rivera E., Mejia J.A., Arun B., et al. Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: final results. J Clin Oncol 24 Suppl. 18 (2006) 21s [abstract 574]
7. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 16 (2008) 1663-1671
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
9. Schuette W., Nagel S., Blankenburg T., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 (2005) 8389-8395
10. Lilenbaum R., Rubin M., Samuel J., et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2 (2007) 306-311
11. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 (2005) 5983-5992
12. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 (2008) 1642-1649
13. Belani C.P., Ramalingam S., Perry M.C., et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 468-473
14. Rosenberg P., Andersson H., Boman K., et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41 (2002) 418-424
15. Hainsworth J.D., Burris III H.A., Yardley D.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19 (2001) 3500-3505
16. Hurria A., Fleming M.T., Baker S.D., et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12 (2006) 6100-6105
17. Hainsworth J.D., Burris H.A.F., Litchy S., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 89 (2000) 328-333
18. Karampeazis A., Vamvakas L., Agelidou A., et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): a randomized phase II Hellenic Oncology Research Group trial. J Clin Oncol 25 Suppl. 18 (2007) 413s [abstract 7615]
19. Nuzzo F., Morabito A., De Maio E., et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol 66 2 (2008) 171-178
20. Perez E., Vogel C.L., Irwin D.H., Kirshner J.J., and Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73 (2002) 85-88
21. ten Tije A.J., Smorenburg C.H., Seynaeve C., et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40 (2004) 352-357
22. Del Mastro L., Perrone F., Repetto L., et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16 2 (2005) 253-258
23. Del Mastro L., and Perrone F. Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. Ann Oncol 16 (2005) 1979-1980
24. Juan O., Albert A., Campos M., Caranyana J.M., Muñoz V., and Alberola V J. Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. Acta Oncol 46 3 (2007) 367-373
25. Bruno R., Vivier N., Veyrat-Follet C., Montay G., and Rhodes G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 19 2 (2001) 163-169
26. ten Tije A.J., Verweij J., Carducci M.A., et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23 6 (2005) 1070-1077
27. Minami H., Ohe Y., Niho S., et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?. J Clin Oncol 22 14 (2004) 2901-2908
28. Slaviero K.A., Clarke S.J., McLachlan A.J., Blair E.Y., and Rivory L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57 1 (2004) 44-53
29. Lichtman S.M., Hollis D., Miller A.A., et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 24 12 (2006) 1846-1851
30. Nakamura Y., Sekine I., Furuse K., and Saijo N. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 46 2 (2000) 114-118
31. Fidias P., Supko J.G., Martins R., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 7 12 (2001) 3942-3949
32. Smorenburg C.H., ten Tije A.J., Verweij J., et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39 2 (2003) 196-202
33. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7 8 (2006) 1041-1053
34. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 31 (2005) 7794-7803
35. Gradishar W., Krasnojon D., Cheporov S., et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 25 Suppl. 18 (2007) 1032
36. Aapro M., Tjulandin S., Bhar P., and Gradishar W. Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 6 Suppl. 7 (2008) 177